Literature DB >> 3052631

Interleukin-6 (B-cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3).

S Shimizu1, T Hirano, R Yoshioka, S Sugai, T Matsuda, T Taga, T Kishimoto, S Konda.   

Abstract

A T lymphoma cell line (KT-3) established from a patient with Lennert's lymphoma showed macrophage-dependent growth. Macrophage-derived factors were able to replace the macrophage functions. Experiments using a variety of cytokines demonstrated that KT-3 proliferated in response to recombinant interleukin-2 (rIL-2), rIL-4, or rIL-6 but did not proliferate in response to rIL-1 alpha, rIL-1 beta, rIL-3, recombinant granulocyte colony-stimulating factor (rG-CSF), rGM-CSF, recombinant interferon-alpha (rIFN-alpha), rIFN-gamma, recombinant tumor necrosis factor (rTNF-alpha), or native IFN-beta. Polyclonal rabbit anti-IL-6 antibody almost completely neutralized the activities of macrophage-derived factors or IL-6 but not IL-2 or IL-4. Scatchard plot analysis demonstrated that KT-3 cells indeed express IL-6 receptors. The results indicate that the macrophage-derived factor that supports the growth of KT-3 is IL-6 and suggest that macrophage-derived IL-6 may play an important role in the histopathogenesis of Lennert's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052631

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Ki-1 lymphoma with nodular involvement in liver and spleen: possible role of cytokines in systemic manifestation of fever and leukocytosis.

Authors:  Y Harada; S Yamada; S Murakami; S Mine; Y Momosaka; J Tsukada; I Morimoto; S Eto
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

2.  Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.

Authors:  D M Nachbaur; M Herold; A Maneschg; H Huber
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

Review 3.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

4.  CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2.

Authors:  E N Tsitsikov; D A Wright; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

5.  Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma.

Authors:  M el-Far; M Fouda; R Yahya; H el-Baz
Journal:  J Physiol Biochem       Date:  2004-12       Impact factor: 4.158

6.  In vitro selection of a peptide inhibitor of human IL-6 using mRNA display.

Authors:  Teruaki Kobayashi; Minako Kakui; Tatsuro Shibui; Yasunori Kitano
Journal:  Mol Biotechnol       Date:  2011-06       Impact factor: 2.695

7.  Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth.

Authors:  H Merz; A Fliedner; K Orscheschek; T Binder; W Sebald; H K Müller-Hermelink; A C Feller
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

8.  Interleukin-7 (IL-7)-induced proliferation of CD8+ T-chronic lymphocytic leukemia cells.

Authors:  R Yoshioka; S Shimizu; J Tachibana; Y Hirose; M Fukutoku; Y Takeuchi; S Sugai; T Takiguchi; S Konda
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

9.  Recombinant interleukin-6 inhibits the growth of rat mesangial cells in culture.

Authors:  M Ikeda; U Ikeda; T Ohara; E Kusano; S Kano
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

10.  Interleukin-4 may contribute to the abundant T-cell reaction and paucity of neoplastic B cells in T-cell-rich B-cell lymphomas.

Authors:  W R Macon; J B Cousar; J A Waldron; S M Hsu
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.